Splitting a weekly testosterone dose, the owner's position
Flatten the peak and trough of a short acting testosterone ester without changing the total dose
The owner's own stated position, signed, with the limit he states on the site already attached. Results fields stay empty until his own numbers exist.
Not advice. This is a record of a schedule, not a dose for you.
The schedule, as reported
Each field below is what the source states, not a rounded version of it. Where the source does not publish a detail, the field says so instead of filling the gap.
- Amount
- The same prescribed weekly total, divided. Splitting is not a reason to take more.
- Frequency
- Two or three smaller injections a week in place of one weekly, or in place of one every two weeks
- Route
- Whichever route the prescription specifies, intramuscular or subcutaneous
- Duration
- Ongoing. This is a schedule rather than a course.
What was measured
Total testosterone, free testosterone, bioavailable testosterone and SHBG, on two draws eighteen months apart. The first was taken before any testosterone was prescribed. The second was taken after starting 100 mg of testosterone cypionate a week. No draw time relative to the last injection was recorded on either, and no oestradiol or haematocrit was captured, which is the gap that matters most here and is stated again in the limits below.
What was reported
Reports, not findings. Nothing below was produced by a controlled comparison.
Before any treatment, 3 February 2025: total testosterone 244 ng/dL against a reference range of 250 to 1100, so below the bottom of the range. Free testosterone 40.6 pg/mL, at the low end.
On 100 mg of testosterone cypionate a week, 6 August 2026: total testosterone 815 ng/dL, mid range. Free testosterone 91.5 pg/mL, inside the range but in its lower half. Bioavailable testosterone 176.2 ng/dL. SHBG 46, mid range.
Total testosterone more than tripled, 244 to 815. Free testosterone more than doubled, 40.6 to 91.5.
What those two numbers do NOT show is anything about splitting the dose. Both draws bracket the start of treatment itself, so they compare being on testosterone against not being on it. There is no single weekly injection arm to compare the split schedule against, and without a recorded draw time there is no way to tell where in the cycle either sample sits. Read as a before and after of starting TRT, this is real. Read as evidence for splitting, it is not evidence at all.
One number in there is worth more than the headline. Free testosterone sits in the lower half of its range while total testosterone sits mid range, with SHBG at 46. That is the pattern where a higher total does not deliver a proportionally higher free fraction, and it is the reason total testosterone alone is a poor way to judge a protocol.
The reasoning he states: cypionate and enanthate have half-lives around eight days, so a large dose at a long interval sends serum testosterone above the target range early in the cycle and lets it fall toward the bottom before the next one.
Splitting changes the interval and not the total. That distinction is the whole position.
Where this comes from
The owner's stated position, already published on the testosterone and testosterone cypionate pages of this site. Its supporting reference is a 2026 Cureus practice review on individualising injectable testosterone in primary care.
That review states that every two week dosing is convenient and should not be the automatic default for a short acting ester, that weekly is often reasonable, and that persistent symptom cycling may reflect dose timing and peak to trough variation rather than an inadequate weekly total. It is a narrative practice review, not a randomised comparison of schedules.
What this protocol cannot tell you
Required on every entry in this registry, and never empty.
The owner's own numbers now sit on this page, and they do not test the position this page is about. Both draws bracket the start of treatment, so they show that testosterone replacement raised his testosterone, which was never in dispute. They contain no comparison against a single weekly injection, no recorded draw time relative to the last shot, no oestradiol and no haematocrit. Draw timing is the whole argument for splitting, so a level without a timestamp cannot support or refute it. No randomised trial of split against single weekly dosing with symptom endpoints exists either, so the position rests on pharmacokinetic reasoning plus practice guidance, not trial evidence. It says nothing about what the right total dose is. One person's numbers are an anecdote with a lab attached; they are published here because this site asks everyone else to show their evidence, not because they settle anything.
The compounds in this protocol
Each profile carries the full evidence record, the legal status and what the trials did not show.
- Testosterone
The best-evidenced hormone on this site. A 5,246-man randomised trial settled the cardiovascular question, and 36 randomised trials in 8,480 women cover the half of the population nobody talks about.
- Testosterone cypionate
The most prescribed injectable testosterone in the United States. Its eight-day half-life is why a single weekly shot produces a peak and a crash, and why splitting the same total flattens the curve.